ImmuCell Reports Strong Sales Growth and Recovery

Immucell ( (ICCC) ) has released its Q4 earnings. Here is a breakdown of the information Immucell presented to its investors.

ImmuCell Corporation, a company in the animal health sector, focuses on developing products that enhance the health and productivity of dairy and beef cattle. The company recently reported a significant increase in its financial performance for the quarter and year ending December 31, 2024.

ImmuCell’s product sales surged by 52% in both the fourth quarter and the full year of 2024, reaching approximately $7.8 million and $26.5 million, respectively, compared to the previous year. This growth marks a recovery from previous production limitations due to contamination events. The company also reported an improvement in gross margins from 25% to 37% in the fourth quarter, contributing to a positive EBITDA for the quarter and the year.

Key financial metrics reveal that ImmuCell achieved a net income of $515,000 in the fourth quarter, a turnaround from a net loss in the same period the previous year. Additionally, the company’s cash and cash equivalents rose to $3.8 million, and stockholders’ equity increased to $27.5 million by the end of 2024.

Looking ahead, ImmuCell is focused on obtaining FDA approval for its Re-Tain product, which is expected to enhance its market offerings. The company is optimistic about its production capabilities and aims to further improve its financial performance in the coming year.